Search

Author/Creator Fleming, G F

1. 944PQUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. (23rd October 2018)

Authors:
Moore, K N; Secord, A A; Geller, M; Miller, D S; Cloven, N G; Fleming, G F; Wahner Hendrickson, A E; Azodi, M; DiSilvestro, P; Oza, A; Cristea, M; Berek, J S; Chan, J K; Rimel, B J; Li, Y; Luptakova, K; Clark, R; Matulonis, U A; Monk, B J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. (7th February 2019)

Authors:
Liu, J F; Barry, W T; Birrer, M; Lee, J -M; Buckanovich, R J; Fleming, G F; Rimel, B J; Buss, M K; Nattam, S R; Hurteau, J; Luo, W; Curtis, J; Whalen, C; Kohn, E C; Ivy, S P; Matulonis, U A
Journal:
Annals of oncology
Issue:
Volume 30:Number 4(2019)
Page Start:
551
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies. Issue 1 (17th March 2014)

Authors:
Karovic, S; Wen, Y; Karrison, T G; Bakris, G L; Levine, M R; House, L K; Wu, K; Thomeas, V; Rudek, M A; Wright, J J; Cohen, E E W; Fleming, G F; Ratain, M J; Maitland, M L
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 96:Issue 1(2014)
Page Start:
27
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗